Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 921

MOTION in Limine No. 22: Preclude Roche From Introducing, Including in Its Invalildity Opening, Testimony, Evidence or Argument on Pegylation During the Validity Phase of the Trial and to Exclude any Proffered Testimony by Dr. Robert Langer During the Trial by Amgen Inc..(Gottfried, Michael)

Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Doc. 921

Case 1:05-cv-12237-WGY

Document 921

Filed 08/31/2007

Page 1 of 4

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

AMGEN INC., Plaintiff, v. F. HOFFMANN-LA ROCHE LTD, a Swiss Company, ROCHE DIAGNOSTICS GMBH, a German Company, and HOFFMANN LA ROCHE INC., a New Jersey Corporation, Defendants.

) ) ) ) ) ) ) ) ) ) ) ) ) )

Civil Action No.: 1:05-cv-12237 WGY

PLAINTIFF AMGEN INC.'S MOTION IN LIMINE NO. 22: PRECLUDE ROCHE FROM INTRODUCING, INCLUDING IN ITS INVALIDITY OPENING, TESTIMONY, EVIDENCE OR ARGUMENT ON PEGYLATION DURING THE VALIDITY PHASE OF THE TRIAL AND TO EXCLUDE ANY PROFFERED TESTIMONY BY DR. ROBERT LANGER DURING THE TRIAL Pursuant to FED. R. EVID. 401, 402, and 403 and FED. R. CIV. P. 26(a)(2)(B) and 37(c)(1), Amgen moves to preclude Roche from introducing testimony, evidence, or argument during the validity phase of the trial, including during Roche's opening statement. The Court's August 27, 2007, Order rendered moot and irrelevant any lay or expert evidence during the validity phase of the trial on the question whether one of ordinary skill in the art could pegylate EPO in 1984, and whether Dr. Lin was in possession of the invention of pegylated EPO. The report and opinion of Dr. Robert Langer, one of Roche's expert witnesses, was limited to the enablement and written description of PEG-modified proteins in the patents-in-suit, thus any testimony that Dr. Langer could give can have no relevance to the validity of the patents. Amgen requests an order under Fed. R. Evid. 401, 402, and 403 and Fed. R. Civ. P. 26(a)(2)(B) and 37(c)(1):

-1MPK 131678-1.041925.0023

Dockets.Justia.com

Case 1:05-cv-12237-WGY

Document 921

Filed 08/31/2007

Page 2 of 4

precluding Roche from mentioning pegylation and/or pegylated erythropoietin ("peg-EPO") during its opening statement or at any other time during the validity phase of the trial; excluding the testimony of Dr. Robert Langer from any phase of the trial; precluding any testimony by Dr. Alexander Klibanov based on or referring to opinions of Dr. Robert Langer during any phase of the trial; striking the entirety of the March 28, 2007 deposition testimony of Amgen witness Graham Molineux designated by Roche from the validity phase of the trial; and striking the March 29, 2007 deposition testimony of Amgen witness Stephen Elliott designated by Roche at pages 129-133, 159, 185-193, and 197-199 from the validity phase of the trial. In support of this motion, Amgen submits a brief.

-2MPK 131678-1.041925.0023

Case 1:05-cv-12237-WGY

Document 921

Filed 08/31/2007

Page 3 of 4

DATED:

August 31, 2007

Respectfully Submitted, AMGEN INC., /s/ Michael R. Gottfried D. Dennis Allegretti (BBO# 545511) Michael R. Gottfried (BBO# 542156) Patricia R. Rich (BBO# 640578) DUANE MORRIS LLP 470 Atlantic Avenue, Suite 500 Boston, MA 02210 Telephone: [phone] Facsimile: [phone] Lloyd R. Day, Jr. (pro hac vice) DAY CASEBEER MADRID & BATCHELDER LLP 20300 Stevens Creek Boulevard, Suite 400 Cupertino, CA 95014 Telephone: [phone] Facsimile: [phone] William G. Gaede III (pro hac vice) McDERMOTT WILL & EMERY 3150 Porter Drive Palo Alto, CA 94304 Telephone: [phone] Facsimile: [phone] Kevin M. Flowers (pro hac vice) MARSHALL, GERSTEIN & BORUN LLP 233 South Wacker Drive 6300 Sears Tower Chicago, IL 60606 Telephone: [phone] Facsimile: [phone]

Of Counsel: Stuart L. Watt Wendy A. Whiteford Monique L. Cordray Darrell G. Dotson Kimberlin L. Morley Erica S. Olson AMGEN INC. One Amgen Center Drive Thousand Oaks, CA 91320-1789 [phone]

-3MPK 131678-1.041925.0023

Case 1:05-cv-12237-WGY

Document 921

Filed 08/31/2007

Page 4 of 4

CERTIFICATE PURSUANT TO LOCAL RULE 7.1 I certify that counsel for the parties have conferred in an attempt to resolve or narrow the issues presented by this motion and no agreement was reached. /s/ Michael R. Gottfried Michael R. Gottfried

CERTIFICATE OF SERVICE I hereby certify that this document filed through the Electronic Case Filing (ECF) system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non-registered participants, on the above date. /s/ Michael R. Gottfried Michael R. Gottfried

-4MPK 131678-1.041925.0023